Grifols ( Grifols)

Primary tabs

Grifols's picture

Management

Contact Address

About Grifols

Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. We accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care.

Grifols press release, blog etc

Thu, 03/10/2022 - 09:00 Grifols XEMBIFY receives European approvals, expanding access to innovative therapies
Wed, 03/02/2022 - 11:14 Grifols partners with Feeding America to help address hunger in the U.S.
Thu, 02/24/2022 - 16:27 Grifols signs global collaboration agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis
Tue, 01/18/2022 - 15:40 Grifols Egypt begins taking plasma donations
Tue, 01/04/2022 - 05:46 Grifols acquires its first plasma donation center in Canada
Thu, 12/02/2021 - 00:25 Grifols receives first certifications for new In Vitro Diagnostics Medical Devices European Regulation
Mon, 11/29/2021 - 20:16 Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma
Tue, 11/23/2021 - 22:08 Grifols launches new home-care treatment service for patients with alpha-1 antitrypsin deficiency in Spain
Wed, 11/17/2021 - 14:44 Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion
Mon, 11/15/2021 - 00:45 Grifols is included on the Dow Jones Sustainability World Index
Tue, 10/26/2021 - 02:58 Grifols earns approval for the voluntary public tender offer of Biotest and advances its strategy to increase the availability of plasma-derived medicines
Mon, 10/18/2021 - 23:31 Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
Tue, 10/05/2021 - 06:36 Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest
Thu, 09/30/2021 - 16:10 GigaGen Licenses ProteoNics 2G UNic Technology Platform for High Yield Production of GigaGens Mono- and Polyclonal Antibody Drug Candidates
Tue, 09/28/2021 - 04:01 Grifols begins commercializing TAVLESSE in France, Italy and Spain to treat chronic immune thrombocytopenia
Mon, 09/27/2021 - 11:39 Grifols earns its first Fitch corporate rating with a BB- and stable outlook
Mon, 08/16/2021 - 06:36 Grifols advances on its strategic investment from GIC with 90% of consents from its notes holders and lenders
Wed, 08/11/2021 - 07:25 GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19